RxDoctor Payments Data

Jeffrey Mulholland, MD

Family Medicine · Canastota, NYNPI 1326000431

Payments from drug & device makers

$748in general payments, 2019–2025

Across 38 payments — averaging $19.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$137
  • Axsome Therapeutics, Inc.$92
  • Novo Nordisk$87
  • Astellas Pharma US Inc$80
  • Pfizer$64
  • Baxter Healthcare$64
  • plus $224 from 7 others

What the payments were for

  • Food & beverage$65688%
  • Education$9212%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$748 in reported general payments places this provider in the 60th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$87,644
Medicare patients
268
Services billed
1,061

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide65$89,928
EliquisApixaban82$81,506
TrulicityDulaglutide47$69,063
JardianceEmpagliflozin57$59,701
XareltoRivaroxaban55$56,692
JanuviaSitagliptin Phosphate40$52,107
FarxigaDapagliflozin Propanediol27$33,410
InvokanaCanagliflozin15$24,383
Breo ElliptaFluticasone/Vilanterol42$23,593
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$19,024
TradjentaLinagliptin24$17,949
MounjaroTirzepatide12$15,789
Spiriva RespimatTiotropium Bromide17$14,977
MyrbetriqMirabegron21$14,629
LinzessLinaclotide20$14,366

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$87$89,92865 claims
Lilly USA, LLCTrulicity, Mounjaro$14$84,85259 claims
PfizerEliquis$64$81,50682 claims
Johnson & JohnsonXarelto, Invokana$27$81,07470 claims
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta$32$47,83283 claims
AstraZenecaFarxiga, Symbicort$137$42,19351 claims
AbbVieLinzess, Synthroid$35$18,65169 claims
Astellas Pharma US IncMyrbetriq$80$14,62921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,321 family medicine providers in New York.

Other family medicine in Canastota

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →